Cleveland Clinic Nephrology Update 2024

Overview

Cleveland Clinic Nephrology Update 2024 delivers a comprehensive review of the latest data and current topics relevant to clinical nephrology practice. This course includes expert presentations on diagnosis and management strategies for patients with kidney disease, emphasizing practical applicability in everyday clinical settings.

On-demand nephrology education — accessible anytime, anywhere.

Format: 10 videos + PDF

Total size: Runtime around 15-20 hours

Agenda

This detailed agenda outlines the sessions and expert talks featured in Cleveland Clinic Nephrology Update 2024.

• Cleveland Clinic Nephrology Update Journal Club — Jagmeet Dhingra MD, Jonathan Taliercio DO
• Welcome — Ali Mehdi MD, MEd
• Precision Medicine: Genetics and Nephrology — Arlene Chapman MD
• Genetics Program Overview: Pre/Post Counseling — Mary-Beth Roberts MS, CGC
• ADPKD Update — Arlene Chapman MD
• Genetics in Tubulointerstitial/Atypical Cystic Disease/ Kidney Stones — Xiangling Wang MD, PhD
• Questions and Answers — Arlene Chapman MD, Xiangling Wang MD, PhD, Mary-Beth Roberts MS, CGC
• HRS Update — Andrew Allegretti MD, MSC
• Cardiac Axis in HRS: The Hepato-Cardio-Renal Syndrome — Andrew Allegretti MD, MSC
• Case Discussions in AKI and Cirrhosis in the ICU: MARS/Terlipressin/RRT — Anchal Kapoor MD, Andrew Allegretti MD, MSC, Christina Lindenmeyer MD
• Questions and Answers — Anchal Kapoor MD, Andrew Allegretti MD, MSC, Christina Lindenmeyer MD
• Kasperzak Lecture: Lupus Nephritis Update — Brad Rovin MD, FACP, FASN
• Clinicopathologic Case Discussions — Marc A. Pohl MD, Corey Cavanaugh DO, Richard Glassock MD, MACP, Brad Rovin MD, FACP, FASN, Leal Herlitz MD
• Questions and Answers — Marc A. Pohl MD, Corey Cavanaugh DO, Richard Glassock MD, MACP, Brad Rovin MD, FACP, FASN, Leal Herlitz MD
• Update on C3 Glomerulopathy — Carla Nester MD, MSA, FASN
• IgA Nephropathy Update — Richard Glassock MD, MACP
• ANCA Vasculitis: Update on Management and Controversies — Carol Langford MD
• Questions and Answers — Carol Langford MD, Carla Nester MD, MSA, FASN, Richard Glassock MD, MACP
• Nephrology-Rheumatology Case Discussions — Emily Littlejohn DO, MPH, Carol Langford MD, Corey Cavanaugh DO, Brad Rovin MD, FACP, FASN
• Thrombotic Microangiopathy and Complement Immunology — Carla Nester MD, MSA, FASN
• Clinicopathologic Case Discussions — Marc A. Pohl MD, Carla Nester MD, MSA, FASN, Richard Glassock MD, MACP, Brad Rovin MD, FACP, FASN, Leal Herlitz MD
• Prophylaxis in Glomerular Diseases — Corey Cavanaugh DO
• Emerging Pharmacologic Therapies in Hypertension — George Thomas MD
• Prescribing GLP1-RA and SGLT2i: A Practical Guide for the Nephrologist — Kevin Pantalone DO
• Questions and Answers — Kevin Pantalone DO, George Thomas MD
• Procedural Therapies for Hypertension: An Update — Luke Laffin MD
• Challenging Hypertension Cases: Panel Discussion — Luke Laffin MD, George Thomas MD
• Questions and Answers — Luke Laffin MD, George Thomas MD
• Obesity and CKD — Sankar Navaneethan MD, MS, MPH
• Update on Obesity Management — Bartolome Burguera MD, PhD
• Questions and Answers — Bartolome Burguera MD, PhD, Sankar Navaneethan MD, MS, MPH
• Update on Hyperaldosteronism

Learning Objectives

• Describe the role of precision medicine in the care of patients with genetic kidney diseases, including major hereditary renal syndromes.
• Summarize the most recent advances in treatment of polycystic kidney disease.
• Identify management strategies of hepatorenal syndrome, including therapies such as MARS, Terlipressin, and CRRT.
• Describe and critically appraise updates in nephrology, including future therapies of C3GN, pathogenesis and management of IgA nephropathy, and advances in kidney transplantation.
• Identify controversies in management of ANCA-associated vasculitis and the role of emerging therapies.
• Describe the role of the complement pathway in development of thrombotic microangiopathy.
• Recognize different facets of glomerular disease management beyond immuno-modulatory therapy.
• Summarize emerging pharmacological and procedural therapies in hypertension management.
• Review clinical guidelines for screening and management of primary hyperaldosteronism.
• Examine updated management guidelines for obesity in CKD patients, including role of SGLT2i and GLP1-RA.

Speakers

This program features a diverse group of expert clinicians and researchers specializing in nephrology and related fields, delivering evidence-based content relevant for clinical practice. Speakers include nephrologists, genetic counselors, and specialists in hypertension, immunology, and metabolic disorders. The course is presented by the Cleveland Clinic.

Target Audience

This activity is designed for nephrologists, rheumatologists, cardiologists, hepatologists, intensive care specialists, internists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with kidney-related conditions.

Why This Topic Matters

Cleveland Clinic Nephrology Update 2024 addresses the evolving landscape of nephrology by providing updated clinical insights and management strategies essential for specialists in this field. The course supports clinicians in maintaining and strengthening their expertise in diagnosis, genetic considerations, and treatment approaches for kidney diseases.

This educational product available through MedHub Central offers accessible and comprehensive nephrology content, reinforcing professional knowledge and enhancing decision-making in clinical practice.